OPEN END TURBO OPTIONSSCHEIN SHORT - VERTEX PHARMACEUTICALS | Real-time BOERSE MUENCHEN 03:02:57 2024-07-17 am EDT | ||
| 3.25 EUR | +5.52% |
|
| Current month | -30.94% | ||
| 1 month | -19.79% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 3.25 | +5.52% |
| 24-07-16 | 3.08 | +8.07% |
| 24-07-15 | 2.85 | -4.36% |
| 24-07-12 | 2.98 | +3.11% |
| 24-07-11 | 2.89 | -6.77% |
Real-time BOERSE MUENCHEN
Last update July 17, 2024 at 03:02 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | Goldman Sachs |
| WKN | GG1YXB |
| ISIN | DE000GG1YXB3 |
| Date issued | 2024-01-08 |
| Strike | 521.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 9.42 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 12.19 € |
|---|---|
| Lowest since issue | 2.66 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
489
USD
Average target price
473.5
USD
Spread / Average Target
-3.17%
- Stock Market
- Certificates
- Certificat
